Key result
Intravenous nifekalant hydrochloride effectively prevented refractory ventricular tachycardia/fibrillation without proarrhythmia or hemodynamic deterioration in 70% of treated patients.
Why the study?
Does intravenous nifekalant hydrochloride prevent refractory VT/VF in patients with acute coronary syndrome or chronic structural heart disease?
Observational (n=30)
Does intravenous nifekalant hydrochloride prevent refractory VT/VF in patients with acute coronary syndrome or chronic structural heart disease?
Intravenous nifekalant is effective for emergent treatment of drug-refractory VT/VF, though the risk of proarrhythmic torsade de pointes must be monitored.
No takes yet. Share an insight, caveat, or question.
NIF may aid refractory VT/VF control with QT monitoring; leaves open need for RCTs versus established agents.
Ohashi et al. (2006) conducted an observational in Refractory ventricular tachycardia/fibrillation (VT/VF) (n=30). Nifekalant hydrochloride (NIF) was evaluated on Prevention of VT/VF without proarrhythmia and hemodynamic deterioration. Intravenous nifekalant hydrochloride effectively prevented refractory ventricular tachycardia/fibrillation without proarrhythmia or hemodynamic deterioration in 70% of treated patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: